Polycystic Kidney Disease, Vitamin D deficiency, hypertension
Conditions
Interventions
A seventy-four (74) adult patients evaluated at the Nephrology Division from Universidade Federal de São Paulo, who had received a diagnosis of ADPKD were selected to participate in the present study.
Magister Handling Pharmacy Ltd., São Paulo, Brazil) and it was given to these patients by the principal researcher (by o
Other
C18.654.521.500.133.770
C12.777.419.403
Sponsors
Universidade Federal de São Paulo
Universidade Federal de São Paulo
Eligibility
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Volunteeers with Autosomal Dominant Polycystic Kidney Disease; both genders; aged between 18 to 75 years; normo or hypertensives; vitamin D deficient [25(OH) < 30ng/ml).
Exclusion criteria
Exclusion criteria: Age 10 mg/dL; serum phosphorous > 5,5 mg/dL; pregnancy; bowel disease; malignances; current/past use of vitamin D or calcium supplements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Beneficial effect of vitamin D3 supplementation on lowering blood pressure and inflammatory markers. The parameters of blood pressure were assessed by ambulatory blood pressure monitoring(ABPM)in baseline period and after 3 months of supplementation. It is was expected that systolic and diastolic blood pressure would lower after vitamin D3 supplementation. With respect to inflammatory markers (Interleukin 6 and 10, tumor necrosis factor alpha, factor nuclear kappa B) that were evaluated in blood samples, it was expected a decrease in these levels after vitamin D3 supplementation. It was also expected that the expression of vitamin D receptor (VDR), vitamin D regulatory enzymes (CYP27B1 and CYP24A1)would increase after supplementation and serum levels of vitamin D [25(OH)D] would achieve levels above 30 ng/ml. ;Fourty-six patients (46) presented hypovitaminosis D [25(OH)< 30 ng/ml], being randomized in vitamin D3 or placebo group. Vitamin D3 supplementation restored serum levels of vitamin D to above 30 ng/ml in 16 patients (76%). There was found no differences in blood pressure parameters (systolic and diastolic), inflammatory markers and in the expression of vitamin D receptor (VDR) and the ezymes CYP27B1 and CYP24A1 after vitamin D3 supplementation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Beneficial effect of sufficient serum levels of vitamin D (> 30ng/ml) upon hipertension, inflammatory markers and renal volume. It was expected a negative correlation between serum levels of vitamin D [25(OH)D] or its receptor (VDR) with inflammatory markers, evaluated in blood sample, blood pressure parameters assessed by ambulatory monitoring blood pressure (ABPM)and renal volume determined by resonance magnetic imaging. ;Serum vitamina D levels [25(OH)D] and VDR expression were not negatively correlated with blood pressure parameters. Serum vitamin D levels [25(OH)D] and VDR expression were negatively correlated with renal volume. Vitamin D receptor (VDR) was negatively correlated with inflammatory markers (IL-6, IL-10, C reactive protein and nuclear factor kappa B. | — |
Countries
Brazil
Contacts
Public ContactPablo Ferraz
Universidade Federal de São Paulo
Outcome results
None listed